Akèy › Maladi Nèwolojik
Etid klinik pou Maladi Nèwolojik ap rekrite nan Etazini
58 etid pou Maladi Nèwolojik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA10 etid
- Washington, DC8 etid
- Dallas, TX7 etid
- Orlando, FL7 etid
- Miami, FL7 etid
- Philadelphia, PA7 etid
- New York City, NY6 etid
- San Diego, CA6 etid
- Chicago, IL6 etid
- St. Louis, MO6 etid
- Pittsburgh, PA5 etid
- Los Angeles, CA5 etid
- Cincinnati, OH5 etid
- Houston, TX5 etid
- Austin, TX5 etid
- Arlington, VA4 etid
- Tampa, FL4 etid
- Atlanta, GA4 etid
- West Palm Beach, FL4 etid
- Aurora, CO4 etid
- Jacksonville, FL4 etid
- San Antonio, TX4 etid
- Durham, NC4 etid
- Birmingham, AL4 etid
- Memphis, TN3 etid
- Hollywood, FL3 etid
- Stamford, CT3 etid
- Akron, OH3 etid
- Scottsdale, AZ3 etid
- Naples, FL3 etid
- Phoenix, AZ3 etid
- Denver, CO3 etid
- Ann Arbor, MI3 etid
- Staten Island, NY3 etid
- Newark, NJ3 etid
- Columbus, OH3 etid
- Seattle, WA3 etid
Pa eta
- Alabama5 etid
- Arizona5 etid
- Colorado8 etid
- Connecticut4 etid
- Florid14 etid
- Georgia5 etid
- Illinois6 etid
- Kalifòni10 etid
- Kansas3 etid
- Maryland11 etid
- Massachusetts12 etid
- Michigan7 etid
- Minnesota3 etid
- Missouri7 etid
- New Jersey7 etid
- New York8 etid
- North Carolina7 etid
- Ohio8 etid
- Oregon3 etid
- Pennsylvania11 etid
- South Carolina4 etid
- Tennessee4 etid
- Texas13 etid
- Virginia5 etid
- Washington6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Ap rekriteFaz 2
Laj 55 a 90 · Tout sèks · Mizajou Sep 30, 2026 · NCT06887192Evaluation and Treatment of Neurosurgical Disorders
Ap rekriteEtid obsèvasyon
Laj 4 a 99 · Tout sèks · Mizajou Sep 29, 2026 · NCT00060541The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
6 Weeks · Tout sèks · Mizajou Sep 29, 2026 · NCT00271622An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
Ap rekriteFaz 1/2
6 Months · Tout sèks · Mizajou Sep 24, 2026 · NCT05757141A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Ap rekriteFaz 2
Laj 55 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589595NightWare and Cardiovascular Health in Veterans With PTSD
Ap rekriteVolontè an sante akeyi
Laj 22 a 88 · Tout sèks · Mizajou Sep 22, 2026 · NCT06419959Product Surveillance Registry
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 18, 2026 · NCT01524276A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 15, 2026 · NCT06916806A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 11, 2026 · NCT07804615A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Ap rekriteFaz 2/3
Laj 18 a 70 · Tout sèks · Mizajou Sep 11, 2026 · NCT07598708Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07098806HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Ap rekriteFaz 1
36 Months – 22 Years · Tout sèks · Mizajou Sep 4, 2026 · NCT03911388A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 1, 2026 · NCT07459647Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ap rekriteEtid obsèvasyon
7 Months – 15 Months · Tout sèks · Mizajou Aug 31, 2026 · NCT06805695Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Aug 28, 2026 · NCT07132775Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
Ap rekrite
Laj 50 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06993142A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Ap rekriteFaz 1
Laj 50 a 85 · Tout sèks · Mizajou Aug 24, 2026 · NCT06297590Top-Down Attentional Control of Visual-Processing
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Aug 24, 2026 · NCT01087281Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
30 Days – 99 Years · Tout sèks · Mizajou Aug 24, 2026 · NCT01778504Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia
Ap rekrite
Laj 3 a 21 · Tout sèks · Mizajou Aug 19, 2026 · NCT05527652Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07218133Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Aug 17, 2026 · NCT07759115Ultra-Low Field (ULF) Point-of-Care (POC) MRI System for Brain Morphology and Pathology
Ap rekriteEtid obsèvasyon
Laj 3 a 99 · Tout sèks · Mizajou Aug 7, 2026 · NCT06203626Ask Questions About Clinical Trials
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07343297Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 120 · Tout sèks · Mizajou Aug 5, 2026 · NCT06169150Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.